The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-6

  van Soolingen, Dick ^a,b   Hernandez Pando, Rogelio ^c   Orozco, Hector ^c   Aguilar, Diana ^c   Magis Escurra, Cecile ^b   Amaral, Leonard ^d   Van Ingen, Jakko ^a,b   Boeree, Martin J ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; THIORIDAZINE; NEUROLEPTIC AGENT; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; ANIMAL; ANTIBIOTIC RESISTANCE; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECT; HUMAN; LUNG; MALE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; TREATMENT OUTCOME;

BACILLI (CLASS);

ANIMALS; ANTIPSYCHOTIC AGENTS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG; MALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; THIORIDAZINE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77958612298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012640     Document Type: Article

References (27)

1. Kristiansen JE (1979) Experiments to illustrate the effect of chlorpromazine on the permeability of the bacterial cell wall. Acta Pathol Microbiol Scand (B) 87: 317-319.
2. Amaral L, Kristiansen JE, Viveiros M, Atouguia J (2001) Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as antituberculosis therapy. J Antimicrob Chemother 47: 505-511.
3. World Health Organization (2008) Anti-tuberculosis drug resistance in the World. Fourth Global Report. Geneva: WHO press.
4. Spigelman MK (2007) New tuberculosis therapeutics: a growing pipeline. J Infect Dis 196(Suppl 1): S28-34.
5. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405.
6. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, et al. (2003) Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 917-922.
7. van Ingen J, van der Laan T, Amaral L, Dekhuijzen R, Boeree MJ, et al. (2009) In vitro activity of thioridazine against mycobacteria. Int J Antimicrob Agents 34: 190-191.
8. Ordway D, Costa L, Martins M, Silveira H, Amaral L, et al. (2004) Increased IL-4 production by CD8 and gammadelta T cells in health care workers is associated with the subsequent development of active tuberculosis. J Infect Dis 190: 756-766.
9. Hernandez-Pando R, Orozco H, Sampieri A, Pavon L, Velasquillo C, et al. (1996) Correlation between the kinetics of Th1/Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 89: 26-33.
10. Jarnagin JL, Luchsinger DW (1980) The use of fluorescein diacetate and ethidium bromide as a stain for evaluating viability of mycobacteria. Stain Technol 55: 253-258.
11. Dhaunsi GS, Singh B, Singh AK, Kirschner DA, Singh I (1993) Thioridazine induces lipid peroxidation in myelin of rat brain. Neuropharmacology 32: 439-446.
12. Fabre RA, Pérez TM, Aguilar LD, Rangel MJ, Estrada-Garćia I (2004) Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis. Clin Exp Immunol 136: 215-223.
13. Hernández-Pando R, Aguilar-Leon D, Orozco H, Serrano A, Ahlem C, et al. (2005) 16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis. J Infect Dis 191: 299-306.
14. Hernandez Pando R, Orozco-Esteves H, Maldonado HA, et al. A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin Exp Immunol 2006; 144: 264-272.
15. Martins M, Viveiros M, Kristiansen JE, et al. (2007) The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 21: 771-775.
16. de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Hernandez-Pando R, van Soolingen D, Bakker-Woudenberg IA (2009) Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice. Int J Immunopathol Pharmacol 22: 723-734.
17. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, et al. (2005) Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365: 318-326.
18. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D (2010) Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 35: 524-526.
19. Sohaskey CD (2008) Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration. J Bacteriol 190: 2981-2986.
20. Viveiros M, Amaral L (2001) Enhancement of antibiotic activity against polydrug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 17: 225-228.
21. Dutta NK, Mehra S, Kaushal D (2010) A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One 5(4): e10069. doi:10.1371/journal.pone.0010069.
22. Hadjimitova V, Bakalova R, Traykov T, Ohba H, Ribarov S (2003) Effect of phenothiazines on protein kinase C- and calcium-dependent activation of peritoneal macrophages. Cell Biol Toxicol 19: 3-12.
23. Bettencourt MV, Bosne-David S, Amaral L (2000) Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 16: 69-71.
24. Forrest FM, Forrest IS, Roizin L (1963) Clinical, biochemical and post mortem studies on a patient treated with chlorpromazine. Revue Agressologie 4: 259-264.
25. Glassman AH, Bigger JT, Jr. (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158: 1774-1782.
26. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F (2010) Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 33: 303-314.
27. Iannini PB (2002) Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 1: 121-128.